Randomized, Double-Blind, Placebo-controlled study of encenicline, an α7 nicotinic acetylcholine receptor agonist, as a treatment for cognitive impairment in schizophrenia

Neuropsychopharmacology

Volumn 40, Issue 13, 2015, Pages 3053-3060

  Keefe, Richard S E ^a   Meltzer, Herbert A ^b   Dgetluck, Nancy ^c   Gawryl, Maria ^c   Koenig, Gerhard ^c   Moebius, Hans J ^c   Lombardo, Ilise ^c   Hilt, Dana C ^c  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c FORUM Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ARIPIPRAZOLE; CREATINE KINASE; CREATININE; ENCENICLINE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; QUETIAPINE; RISPERIDONE; BUNGAROTOXIN RECEPTOR; N-(7-CHLORO-N-QUINUCLIDIN-3-YL)BENZO(B)THIOPHENE-2-CARBOXAMIDE; NICOTINIC AGENT; PSYCHOTROPIC AGENT; QUINUCLIDINE DERIVATIVE; THIOPHENE DERIVATIVE;

ABDOMINAL PAIN; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANXIETY DISORDER; APTITUDE TEST; ARTICLE; BACKACHE; COGNITION; COGNITIVE DEFECT; COGSTATE COMPUTERIZED BATTERY; CONSTIPATION; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ECG ABNORMALITY; FEMALE; FEVER; HUMAN; INFLUENZA; INSOMNIA; LEG FRACTURE; MAJOR CLINICAL STUDY; MALE; MATRICS CONSENSUS COGNITIVE BATTERY; MENTAL PATIENT; MULTICENTER STUDY; NAUSEA; OVERALL COGNITION INDEX; PHARYNGITIS; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RHINOPHARYNGITIS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIA COGNITION RATING SCALE; SCORING SYSTEM; SCORS GLOBAL RATING SCALE; SIDE EFFECT; SINGLE BLIND PROCEDURE; SOMNOLENCE; SUPRAVENTRICULAR PREMATURE BEAT; TREATMENT DURATION; TREATMENT OUTCOME; TREND STUDY; UPPER RESPIRATORY TRACT INFECTION; ADOLESCENT; AGONISTS; CLINICAL TRIAL; COGNITION DISORDERS; DRUG EFFECTS; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PSYCHOLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR; ANTIPSYCHOTIC AGENTS; COGNITION; COGNITION DISORDERS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NICOTINIC AGONISTS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTROPIC DRUGS; QUINUCLIDINES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; THIOPHENES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84942911898     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2015.176     Document Type: Article

References (28)

1. Addington D, Addington J, Schissel B (1990). A depression rating scale for schizophrenics. Schizophr Res 3: 247-251.
2. Barbier AJ, Hilhorst J, van Vliet A, Snyder P, Palfreyman MG, Gawryl M et al. (2015). Pharmacodynamics, pharmacokinetics, safety, and tolerability of encenicline, a selective α7 nicotinic receptor partial agonist, in single ascending dose and bioavailability studies. Clin Ther 37: 311-324.
3. Barik J, Wonnacott S (2009). Molecular and cellular mechanisms of action of nicotine in the CNS. Handb Exp Pharmacol 192: 173-207.
4. Bilder RM, Goldman RS, Robinson D, Reiter G, Bell L, Bates JA et al. (2000). Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. Am J Psychiatry 157: 549-559.
5. Cohen J (1977). Statistical Power Analysis for the Behavioral Sciences, 2nd edn. Lawrence Erlbaum Associates: Mahwah, NJ.
6. Green MF, Nuechterlein KH, Gold JM, Barch DM, Cohen J, Essock S et al. (2004). Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry 56: 301-307.
7. Harvey PD, Keefe RS (1997). Cognitive impairment schizophrenia and implications of atypical neuroleptic treatment. CNS Spectrums 2: 1-11.
8. Harvey PD, Sukhodolsky D, Parrella, White L, Davidson M (1997). The association between adaptive and cognitive deficits in geriatric chronic schizophrenic patients. Schizophr Res 27: 211-218.
9. Heinrichs RW, Zakzanis K (1998). Neurocognitive deficits in schizophrenia: a quantitative review of the evidence. Neuropsychology 12: 426-445.
10. Huang M, Felix AR, Flood DG, Bhuvaneswaran C, Hilt D, Koenig G et al. (2014). The novel α7 nicotinic acetylcholine receptor agonist EVP-6124 enhances dopamine, acetylcholine, and glutamate efflux in rat cortex and nucleus accumbens. Psychopharmacology (Berl) 231: 4541-4551.
11. Kay SR, Fiszbein A, Opler LA (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13: 261-276.
12. Keefe RS, Poe M, Walker TM, Kang JW, Harvey PD (2006). The Schizophrenia Cognition Rating Scale: an interview-based assessment and its relationship to cognition, real world functioning, and functional capacity. Am J Psychiatry 163: 426-432.
13. Keefe RSE, Fox KH, Harvey PD, Cucchiaro J, Siu C, Loebel A (2011). Characteristics of the MATRICS consensus cognitive battery in a 29 site antipsychotic schizophrenia clinical trial. Schizophr Res 125: 161-168.
14. Keefe RS, Davis VG, Spagnola NB, Hilt D, Dgetluck N, Ruse S et al. (2015). Reliability, validity and treatment sensitivity of the Schizophrenia Cognition Rating Scale. Eur Neuropsychopharmacol 25: 176-184.
15. Kern RS, Nuechterlein KH, Green MF, Baade LE, Fenton WS, Gold JM et al. (2008). The MATRICS consensus cognitive battery: part 2. Co-norming and standardization. Am J Psychiatry 165: 214-220.
16. Maruff P, Thomas E, Cysique L, Brew B, Collie A, Snyder P et al. (2009). Validity of the CogState brief battery: relationship to standardized tests and sensitivity to cognitive impairment in mild traumatic brain injury, schizophrenia, and AIDS dementia complex. Arch Clin Neuropsychol 24: 165-178.
17. Mohamed S, Rosenheck R, Swartz M, Stroup S, Lieberman JA, Keefe RSE (2008). Relationship of cognition and psychopathology to function impairment in schizophrenia. Am J Psychiatry 165: 978-987.
18. Mohs PE, Cheng CM, Claxton K, Conley RR, Feldman JJ, Hargreaves WA et al. (2004). The heterogeneity of schizophrenia in disease states. Schizophr Res 71: 83-95.
19. Nuechterlein KH, Green MF, Kern RS, Baade LE, Barch DM, Cohen JD et al. (2008). The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry 165: 203-213.
20. Overall JE, Gorham DR (1962). The brief psychiatric rating scale. Psychol Rep 10: 799-812.
21. Picciotto MR, Zoli M, Rimondini R, Lena C, Marubio LM, Pich EM et al. (1998). Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine. Nature 391: 173-177.
22. Pichat P, Bergis OE, Terranova J-P, Urani A, Duarte C, Santucci V et al. (2007). SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia. Neuropsychopharmacology 32: 17-34.
23. Posner K, Oquendo MA, Gould M, Stanley B, Davies M (2007). Columbia classification algorithm of suicide assessment (CCASA). Am J Psychiatry 164: 1035-1043.
24. Preskorn SH, Gawryl M, Dgetluck N, Palfreyman M, Bauer LO, Hilt DC (2014). Normalizing effects of EVP-6124, an alpha-7 nicotinic partial agonist, on event-related potentials and cognition: a proof of concept, randomized trial in patients with schizophrenia. J Psychiatr Pract 20: 12-24.
25. Prickaerts J, van Goethem NP, Chesworth R, Shapiro G, Boess FG, Methfessel C et al. (2012). EVP-6124, a novel and selective α7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of a7 nicotinic acetylcholine receptors. Neuropharmacology 62: 1099-1110.
26. Saykin AJ, Gur RC, Gur RE, Mozley PD, Mozley LH, Resnick SM et al. (1991). Neuropsychological function in schizophrenia. Selective impairment in memory and learning. Arch Gen Psychiatry 48: 618-624.
27. Saykin AJ, ShtaselDL, Gur RE, Kester DB,Mozley LH, Stafiniak P et al. (1994). Neuropsychological deficits in neuroleptic nave patients with first-episode schizophrenia. Arch Gen Psychiatry 51: 124-131.
28. Simpson GM, Angus JWS (1970). A rating scale for extrapyramidal side effects. Acta Psych Scand 212: 11-19.